Lilly Alzheimer’s drug gets full approval, Rocket gene therapy rejected, Eisai, BMS end ADC partnership [The good, the bad, the ugly]

from Off Script: A Pharma Manufacturing Podcast · host Pharma Manufacturing

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA grants Eli Lilly Alzheimer’s drug full approval The bad — FDA rejects Rocket gene therapy The ugly — Eisai, BMS end ADC partnership

Episode metadata supplied by the publisher feed · Published Jul 8, 2024

Embed this episode

Attribution link and audio player

Ready to play

Lilly Alzheimer’s drug gets full approval, Rocket gene therapy rejected, Eisai, BMS end ADC partnership [The good, the bad, the ugly]

0:00 3:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Off Script: A Pharma Manufacturing Podcast?

This episode is 3 minutes long.

When was this Off Script: A Pharma Manufacturing Podcast episode published?

This episode was published on July 8, 2024.

Can I download this Off Script: A Pharma Manufacturing Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!